Literature DB >> 32962984

International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Xavier Norel1, Yukihiko Sugimoto2, Gulsev Ozen2, Heba Abdelazeem2, Yasmine Amgoud2, Amel Bouhadoun2, Wesam Bassiouni2, Marie Goepp2, Salma Mani2, Hasanga D Manikpurage2, Amira Senbel2, Dan Longrois2, Akos Heinemann2, Chengcan Yao2, Lucie H Clapp2.   

Abstract

Prostaglandins are derived from arachidonic acid metabolism through cyclooxygenase activities. Among prostaglandins (PGs), prostacyclin (PGI2) and PGE2 are strongly involved in the regulation of homeostasis and main physiologic functions. In addition, the synthesis of these two prostaglandins is significantly increased during inflammation. PGI2 and PGE2 exert their biologic actions by binding to their respective receptors, namely prostacyclin receptor (IP) and prostaglandin E2 receptor (EP) 1-4, which belong to the family of G-protein-coupled receptors. IP and EP1-4 receptors are widely distributed in the body and thus play various physiologic and pathophysiologic roles. In this review, we discuss the recent advances in studies using pharmacological approaches, genetically modified animals, and genome-wide association studies regarding the roles of IP and EP1-4 receptors in the immune, cardiovascular, nervous, gastrointestinal, respiratory, genitourinary, and musculoskeletal systems. In particular, we highlight similarities and differences between human and rodents in terms of the specific roles of IP and EP1-4 receptors and their downstream signaling pathways, functions, and activities for each biologic system. We also highlight the potential novel therapeutic benefit of targeting IP and EP1-4 receptors in several diseases based on the scientific advances, animal models, and human studies. SIGNIFICANCE STATEMENT: In this review, we present an update of the pathophysiologic role of the prostacyclin receptor, prostaglandin E2 receptor (EP) 1, EP2, EP3, and EP4 receptors when activated by the two main prostaglandins, namely prostacyclin and prostaglandin E2, produced during inflammatory conditions in human and rodents. In addition, this comparison of the published results in each tissue and/or pathology should facilitate the choice of the most appropriate model for the future studies.
Copyright © 2020 The Author(s).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32962984      PMCID: PMC7509579          DOI: 10.1124/pr.120.019331

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  842 in total

1.  Long-term streptozotocin-induced diabetes alters prostanoid production in rat aorta and mesenteric bed.

Authors:  H A Peredo; R Rodríguez; M C Susemihl; I Villarreal; E Filinger
Journal:  Auton Autacoid Pharmacol       Date:  2006-10

2.  Altered post-capillary and collecting venular reactivity in skeletal muscle with metabolic syndrome.

Authors:  Kent A Lemaster; Zahra Farid; Robert W Brock; Carl D Shrader; Daniel Goldman; Dwayne N Jackson; Jefferson C Frisbee
Journal:  J Physiol       Date:  2017-07-05       Impact factor: 5.182

3.  Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction.

Authors:  Tack Lee; Petter Hedlund; Donald Newgreen; Karl-Erik Andersson
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

4.  The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.

Authors:  Kyung-Soo Chun; Huei-Chen Lao; Robert Langenbach
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

5.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

Authors:  B W Christman; C D McPherson; J H Newman; G A King; G R Bernard; B M Groves; J E Loyd
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

6.  Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins.

Authors:  Y Sugimoto; M Negishi; Y Hayashi; T Namba; A Honda; A Watabe; M Hirata; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

7.  Prostaglandin metabolism in children with diabetes mellitus. I. Plasma prostaglandin E2, F2 alpha, TXB2, and serum fatty acid levels.

Authors:  M Arisaka; O Arisaka; Y Fukuda; Y Yamashiro
Journal:  J Pediatr Gastroenterol Nutr       Date:  1986 Nov-Dec       Impact factor: 2.839

8.  Platelet activation and prostacyclin release in essential hypertension.

Authors:  C Lemne; O Vesterqvist; N Egberg; K Green; T Jogestrand; U de Faire
Journal:  Prostaglandins       Date:  1992-09

Review 9.  Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.

Authors:  Carlo Patrono
Journal:  Br J Clin Pharmacol       Date:  2016-07-18       Impact factor: 4.335

10.  BMP-2 induces ATF4 phosphorylation in chondrocytes through a COX-2/PGE2 dependent signaling pathway.

Authors:  T-F Li; K Yukata; G Yin; T Sheu; T Maruyama; J H Jonason; W Hsu; X Zhang; G Xiao; Y T Konttinen; D Chen; R J O'Keefe
Journal:  Osteoarthritis Cartilage       Date:  2014-01-11       Impact factor: 6.576

View more
  4 in total

Review 1.  Roles of EP Receptors in the Regulation of Fluid Balance and Blood Pressure.

Authors:  Lu Wang; Yiqian Wu; Zhanjun Jia; Jing Yu; Songming Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

2.  Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors.

Authors:  Pavel V Ershov; Evgeniy O Yablokov; Leonid A Kaluzhskiy; Yuri V Mezentsev; Alexis S Ivanov
Journal:  Biology (Basel)       Date:  2022-04-13

3.  Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model.

Authors:  Masahito Masato; Yasuyoshi Miyata; Hiroki Kurata; Hidenori Ito; Kensuke Mitsunari; Akihiro Asai; Yuichiro Nakamura; Kyohei Araki; Yuta Mukae; Tsuyoshi Matsuda; Junki Harada; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

Review 4.  EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics.

Authors:  Madison N Sluter; Ruida Hou; Lexiao Li; Nelufar Yasmen; Ying Yu; Jiawang Liu; Jianxiong Jiang
Journal:  J Med Chem       Date:  2021-08-05       Impact factor: 8.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.